Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration.
暂无分享,去创建一个
Tianhong Pan | Xiong Zhang | W. Le | T. Pan | Weidong Le | Wenjie Xie | W. Xie | Xiong Zhang | Shen Qu | Xiaotong Wang | Xiaotong Wang | S. Qu | Shen Qu
[1] D. Perl,et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease , 2004, Annals of neurology.
[2] D. Richardson. Novel Chelators for Central Nervous System Disorders That Involve Alterations in the Metabolism of Iron and Other Metal Ions , 2004, Annals of the New York Academy of Sciences.
[3] J. Trojanowski,et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.
[4] M. L. Schmidt,et al. α-Synuclein in Lewy bodies , 1997, Nature.
[5] G. Irvine,et al. Aggregation and neurotoxicity of α-synuclein and related peptides , 2001 .
[6] T. Arendt,et al. Effect of advanced glycation endproducts on cell cycle and their relevance for Alzheimer's disease. , 2003, Journal of neural transmission. Supplementum.
[7] K. Jellinger,et al. Recent developments in the pathology of Parkinson's disease. , 2002, Journal of neural transmission. Supplementum.
[8] Kazuhiro Iwai,et al. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice , 2001, Nature Genetics.
[9] C. Olanow,et al. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats , 2002, Neuroreport.
[10] T. Sherer,et al. Ubiquitin–proteasome system and Parkinson's diseases , 2005, Experimental Neurology.
[11] E. Masliah,et al. Role of Cytochrome c as a Stimulator of α-Synuclein Aggregation in Lewy Body Disease* , 1999, The Journal of Biological Chemistry.
[12] H J Gundersen,et al. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[13] E. Hirsch,et al. Lack of up‐regulation of ferritin is associated with sustained iron regulatory protein‐1 binding activity in the substantia nigra of patients with Parkinson's disease , 2002, Journal of neurochemistry.
[14] Colin L. Masters,et al. Neurodegenerative diseases and oxidative stress , 2004, Nature Reviews Drug Discovery.
[15] J. Connor,et al. Regional brain iron, ferritin and transferrin concentrations during iron deficiency and iron repletion in developing rats. , 1997, The Journal of nutrition.
[16] M. Youdim,et al. Iron and α-synuclein in the substantia nigra of MPTP-treated mice , 2007, Journal of Molecular Neuroscience.
[17] B. Wolozin,et al. Book Review: Iron and Parkinson’s Disease , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[18] K. Double,et al. The Relevance of Iron in the Pathogenesis of Parkinson's Disease , 2004, Annals of the New York Academy of Sciences.
[19] H. Vorum,et al. Ca2+ Binding to α-Synuclein Regulates Ligand Binding and Oligomerization* , 2001, The Journal of Biological Chemistry.
[20] V. Uversky,et al. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. , 2001, The Journal of biological chemistry.
[21] A. Siderowf,et al. Update on Parkinson Disease , 2003, Annals of Internal Medicine.
[22] C. Olanow,et al. Ubiquitin–proteasome system and Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[23] G. Delitala,et al. A clinical study on the relationship between the pineal gland and the opioid system , 2005, Journal of Neural Transmission.
[24] K. Jellinger,et al. The Role of Iron in Neurodegeneration , 1999, Drugs & aging.
[25] Joseph Jankovic,et al. Neurodegenerative disease and iron storage in the brain , 2004, Current opinion in neurology.